European Companies Search Engine
EU funding (€3,020,639): Single molecule bio-electronic smart system array for clinical testing Hor10 Dec 2018 EU Research and Innovation programme "Horizon"
Text
Single molecule bio-electronic smart system array for clinical testing
Digitizing biomarkers analysis by quantifying them at the single-molecule level is the new frontier for advancing the science of precision health. The SiMBiT project will develop a bio-electronic smart system leveraging on an existing lab-based proof-of-concept that can perform single-molecule detection of both proteins and DNA bio-markers. Specifically, the SiMBiT activities will develop the lab-based device into a cost-effective portable multiplexing array prototype that integrates, with a modular approach, novel materials and standard components/interfaces. The SiMBiT platform exhibits enhanced sensing capabilities: specificity towards both genomic and protein markers along with single-molecule detection limits and time-to-results within two hours. This makes the SiMBiT prototype the world best performing bio-electronic sensing system ever. SiMBiT will reach these ambitious goals with a multidisciplinary research effort involving device-physicists, analytical-chemists, bio-chemists, clinicians, electronic- and system-engineers. The platform is also single-use and cost-effective and can work in low-resource settings. The SiMBiT field-effect sensing system will be fabricated by means of future mass-manufacturable, large-area compatible, scalable techniques such as printing and other direct-writing processes. 3D printing of a module is also foreseen. The SiMBiT prototype will demonstrate, for first time, a matrix of up to 96 bio-electronic sensors and a Si IC chip for the processing of all data coming from the matrix, multiplexing single-molecule detection. As the Si IC pins are limited the chip area is reduced and its cost minimized, enabling a single-use assay plate. SiMBiT will apply the multiplexing single molecule technology to the early detection of human pancreatic neoplasms in a well-defined clinical context, performing simultaneous analysis of genomic and protein markers with a minimal sample volume, reduced costs and reduced time-to-results.
Funded Companies:
| Company name | Funding amount |
| ABO AKADEMI | €350,000 |
| €390,750 | |
| Flexenable Ltd. | €302,092 |
| Flexenable Technology Ltd. | €53,312 |
| €352,500 | |
| HEINRICH-HEINE-UNIVERSITAET DUESSELDORF | €415,765 |
| In Extenso Innovation Croissance | €112,500 |
| Masmec S.p.A. | €262,500 |
| Technische Universiteit Eindhoven | €389,999 |
| Universita Degli Studi DI Brescia | €391,221 |
Source: https://cordis.europa.eu/project/id/824946
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "ABO AKADEMI - EU funding (€3,020,639): Single molecule bio-electronic smart system array for clinical testing"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
